Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 1.00 |
| ▸ | ACAT1 | P24752 | 1/20 | 1.00 |
| ▸ | SOAT1 | P35610 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflucimibe SCHEMBL668294 | 1.00 | SOAT2 (1.00) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| Eflucimibe SCHEMBL29427708 | 1.00 | SOAT2 (1.00) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| Eflucimibe SCHEMBL8041449 | 0.91 | SOAT2 (0.82) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL5900907 | 0.89 | SOAT2 (0.80) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL5900910 | 0.89 | SOAT2 (0.80) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL8079670 | 0.89 | SOAT1 (0.79) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL8416087 | 0.88 | SOAT2 (0.78) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL13269963 | 0.87 | SOAT2 (0.76) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL13193425 | 0.86 | SOAT2 (0.75) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL13249165 | 0.85 | SOAT2 (0.73) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | EFIL BIOSCIENCE INC (KR) | 2026-04-02 | — | — | US | claimed |
| US-12419847-B2 | Composition and method for attenuating neuroinflammation, amyloidopathy and tauopathy | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-09-23 | — | — | US | claimed |
| WO-2024098005-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-10 | — | — | WO | claimed |
| US-20240148833-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-09 | — | — | US | claimed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | claimed |
| WO-2023183843-A1 | COMBINATION THERAPY FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230302021-A1 | COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | claimed |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | PURDUE RESEARCH FOUNDATION | 2023-09-14 | — | — | US | claimed |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| WO-2018057834-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-03-29 | — | — | WO | claimed |
| EP-1434567-B1 | METHOD FOR PREPARING A COMPOUND FOR INTERACTION OF ACTIVE SUBSTANCES WITH A POROUS SUPPORT USING SUPERCRITICAL FLUID | PF MEDICAMENT (FR) | 2007-12-19 | — | — | EP | claimed |
| US-20050274671-A1 | Method for preparing a compound of interaction of active substances with a porous support using supercritical fluid | PIERRE FABRE MEDICAMENT (FR) | 2005-12-15 | — | — | US | claimed |
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | claimed |
| US-6864246-B2 | Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae | PIERRE FABRE MEDICAMENT (FR) | 2005-03-08 | — | — | US | claimed |
| EP-1434567-A1 | METHOD FOR PREPARING A COMPOUND FOR INTERACTION OF ACTIVE SUBSTANCES WITH A POROUS SUPPORT USING SUPERCRITICAL FLUID | PIERRE FABRE MEDICAMENT (FR) | 2004-07-07 | — | — | EP | claimed |
| US-20040127462-A1 | Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae | PIERRE FABRE MEDICAMENT (FR) | 2004-07-01 | — | — | US | claimed |
| WO-2003043604-A1 | METHOD FOR PREPARING A COMPOUND FOR INTERACTION OF ACTIVE SUBSTANCES WITH A POROUS SUPPORT USING SUPERCRITICAL FLUID | PIERRE FABRE MEDICAMENT (FR) | 2003-05-30 | — | — | WO | claimed |
| WO-2003030867-A2 | METHOD FOR PREPARING AN INTERACTIVE COMPOUND OF AN ANILIDE DERIVATIVE WITH A POROUS SUPPORT BY SUPERCRITICAL FLUID | PIERRE FABRE MEDICAMENT (FR) | 2003-04-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | CD274, PDCD1, PDCD4 | SOAT2 3131/4885ACAT1 7/4885SOAT1 1835/4885 |
| US-12419847-B2 | Composition and method for attenuating neuroinflammation, amyloidopathy and tauopathy | MAPT, LCAT, ACAT2 | SOAT2 33/4885ACAT1 4/4885SOAT1 74/4885 |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | ACAT2, ACAT1, LCAT | SOAT2 33/4885ACAT1 2/4885SOAT1 44/4885 |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | ACAT2, ACAT1, LCAT | SOAT2 17/4885ACAT1 2/4885SOAT1 15/4885 |
| US-20040127462-A1 | Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae | APOB, HDLBP, PCSK9 | SOAT2 38/4885ACAT1 458/4885SOAT1 82/4885 |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | GLP1R, GPR119, FABP4 | SOAT2 220/4885ACAT1 25/4885SOAT1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.